Velicept Therapeutics

Velicept Therapeutics, Inc. is a privately held clinical development company dedicated to advancing first-class compounds with the potential to meet unmet medical needs. Its lead program, solabegron, is a highly differentiated novel compound currently under investigation for overactive bladder (OAB) and irritable bowel syndrome (IBS).